Home › Soft Tissue Sarcoma

Soft Tissue Sarcoma clinical trials recruiting in the U.S.

136 studies for Soft Tissue Sarcoma are recruiting participants at sites across the United States.

Soft tissue sarcoma refers to cancer that begins in the muscle, fat, vessels or tendons. It can cause a lump or swelling. See which treatments are available

Cities with the most studies

• Houston, TX32 studies
• New York City, NY20 studies
• Boston, MA17 studies
• Los Angeles, CA13 studies
• St. Louis, MO12 studies
• Columbus, OH12 studies
• Washington, DC11 studies
• Memphis, TN10 studies
• Philadelphia, PA9 studies
• Aurora, CO8 studies
• Nashville, TN8 studies
• Durham, NC8 studies
• Queens, NY8 studies
• Rochester, MN7 studies
• Dallas, TX7 studies
• Atlanta, GA7 studies
• Chicago, IL7 studies
• Grand Rapids, MI7 studies
• Baldwin Park, CA7 studies
• Greenburgh, NY7 studies
• Santa Monica, CA7 studies
• Mountain View, CA6 studies
• Miami, FL6 studies
• Orange, CA6 studies
• Staten Island, NY6 studies
• New Rochelle, NY6 studies
• Edison, NJ6 studies
• East Norwalk, CT6 studies
• Arlington, VA5 studies
• Baltimore, MD5 studies
• Cleveland, OH5 studies
• San Francisco, CA5 studies
• Birmingham, AL5 studies
• Pittsburgh, PA5 studies
• Cincinnati, OH4 studies
• Jacksonville, FL4 studies
• Omaha, NE4 studies
• Charlotte, NC3 studies
• Tampa, FL3 studies
• The Bronx, NY3 studies

By state

• Alabama6 studies
• Arizona5 studies
• California39 studies
• Colorado11 studies
• Connecticut4 studies
• District of Columbia6 studies
• Florida20 studies
• Georgia8 studies
• Illinois9 studies
• Iowa3 studies
• Kansas3 studies
• Maryland10 studies
• Massachusetts18 studies
• Michigan9 studies
• Minnesota10 studies
• Missouri13 studies
• Nebraska4 studies
• New Jersey8 studies
• New York27 studies
• North Carolina13 studies
• Ohio21 studies
• Oregon3 studies
• Pennsylvania15 studies
• Tennessee18 studies
• Texas36 studies
• Utah6 studies
• Virginia7 studies
• Wisconsin4 studies

Recently updated studies

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.